Itulazax (Betula Verrucosa (108))

Betula verrucosa extract in Itulazax modulates the immune response by shifting allergen‑specific activity from IgE‑driven pathways to IgG‑mediated blocking antibodies and enhancing regulatory T‑cell function. This re‑education of the immune system reduces hypersensitivity to birch pollen and promotes long‑term tolerance.

The dosage of Itulazax is individualized and determined by the prescribing healthcare professional based on the patient’s age, severity of allergy, and response to therapy. Patients should follow the exact regimen provided by their clinician and not adjust the dose without medical guidance.

Safety data for Itulazax in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against unknown risks and discuss options with the patient. Use is generally avoided unless the therapeutic advantage justifies potential exposure.

To order Itulazax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Itulazax delivers Betula verrucosa extract via the sublingual route, offering a non‑injectable alternative to traditional subcutaneous immunotherapy. Compared with injectable forms, sublingual administration can be more convenient and may have a lower risk of systemic reactions, though efficacy and safety profiles are comparable when used as directed.

Itulazax should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid exposing it to extreme temperatures to maintain stability and potency.

Itulazax is administered sublingually. The patient places the prescribed dose under the tongue and holds it there for the recommended time before swallowing, allowing the extract to be absorbed through the oral mucosa. Administration instructions are provided by the prescribing clinician.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe oral swelling, bronchospasm, and angioedema. Patients should be educated to recognize early signs of these reactions and seek immediate medical attention if they occur.

Itulazax is contraindicated in individuals with a known hypersensitivity to Betula verrucosa extract or any component of the formulation. Patients with uncontrolled severe asthma or those receiving conflicting allergen immunotherapies should discuss suitability with their healthcare provider before starting treatment.